Clinical Trial Update: Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the safety and immunogenicity of an inactivated, adjuvanted whole Zika virus vaccine candidate (VLA1601) in healthy adults; the study st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Zika Virus Disease

Drugs mentioned

• VLA1601

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Zika, Zika Virus Infection | Phase 1 | Status: COMPLETED